Actively Recruiting
Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer
Led by Jiangsu HengRui Medicine Co., Ltd. · Updated on 2025-12-09
662
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a randomized, open-label, multicenter Phase III clinical trial designed to evaluate the efficacy and safety of Irinotecan Hydrochloride Liposome Injection (II) combined with oxaliplatin and 5-FU/LV versus nab-paclitaxel combined with gemcitabine as first-line treatment for advanced pancreatic cancer.
CONDITIONS
Official Title
Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- ECOG performance status of 0 or 1
- Histologically or cytologically confirmed pancreatic cancer not previously treated for metastatic disease
- Life expectancy of at least 3 months
- Presence of at least one measurable lesion according to RECIST 1.1 criteria
- Able and willing to provide written informed consent
You will not qualify if you...
- Pancreatic cancer originating from extrapancreatic ductal epithelium types such as neuroendocrine carcinoma, acinar cell carcinoma, pancreatoblastoma, or solid-pseudopapillary tumor
- History of central nervous system metastases
- Severe infections (greater than CTCAE grade 2) requiring inpatient treatment within 4 weeks before enrollment or intravenous antibiotics within 2 weeks before enrollment
- Uncontrolled cardiac conditions including NYHA class 2 or higher heart failure, unstable angina, myocardial infarction within 6 months, or significant arrhythmias requiring treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China, 100730
Actively Recruiting
Research Team
Z
Zengquan Gu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here